SCHEMBL7208878

SCHEMBL7208878

Cc1cc(COC2CCN(S(=O)(=O)C3CCNCC3(O)C(=O)NO)CC2)cc(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 8/20 0.43
MMP2 P08253 4/20 0.36
MMP13 P45452 4/20 0.36
DRD4 P21917 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
ADAM10 O14672 2/20 0.33
MMP9 P14780 2/20 0.32
MMP1 P03956 2/20 0.32
HDAC4 P56524 2/20 0.32
AOC3 Q16853 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
SLC6A4 P31645 1/20 0.32
HTR7 P34969 1/20 0.32
HTR2B P41595 1/20 0.32
HTR3A P46098 1/20 0.32
SLC6A3 Q01959 1/20 0.32
HTR4 Q13639 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7208005 0.88 MMP13 (0.42) ADAM17MMP2MMP13ADAM10MMP9
SCHEMBL7202351 0.86 ADAM17 (0.45) ADAM17MMP13
SCHEMBL7200927 0.86 MMP13 (0.46) ADAM17MMP2MMP13MMP1HDAC4
SCHEMBL7207005 0.85 MMP13 (0.42) ADAM17MMP2MMP13MMP1HDAC4
SCHEMBL7200956 0.85 MMP2 (0.46) ADAM17MMP2MMP13TMEM97SIGMAR1
SCHEMBL7206521 0.85 MMP13 (0.48) ADAM17MMP2MMP13MMP9MMP1
SCHEMBL7202610 0.84 MMP13 (0.42) ADAM17MMP2MMP13MMP9MMP1
SCHEMBL7201688 0.84 MMP13 (0.43) ADAM17MMP2MMP13MMP1HDAC4
SCHEMBL7205543 0.84 MMP13 (0.42) ADAM17MMP2MMP13MMP9MMP1
SCHEMBL7205477 0.83 ADAM17 (0.41) ADAM17MMP2MMP13ADAM10MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 ADAM17 162/4885MMP2 13/4885MMP13 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.